

Pol Specenier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3576031/publications.pdf>

Version: 2024-02-01

104
papers

3,838
citations

279798

23
h-index

128289

60
g-index

108
all docs

108
docs citations

108
times ranked

5899
citing authors

#	ARTICLE	IF	CITATIONS
1	Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 368-374.	1.0	14
2	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 13-28.	1.4	1
3	Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2021, 29, 168-177.	1.8	7
4	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	1.6	100
5	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The 11 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	2.8	33
6	The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥70 years) patients with different cancer tumors. <i>Journal of Geriatric Oncology</i> , 2020, 11, 926-936.	1.0	7
7	Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapy (PRESTO trial). <i>Trials</i> , 2020, 21, 237.	1.6	20
8	A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms. <i>Frontiers in Oncology</i> , 2020, 10, 1020.	2.8	19
9	An overview of binimetinib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 747-754.	1.8	8
10	Health related quality of life in older patients with solid tumors and prognostic factors for decline. <i>Journal of Geriatric Oncology</i> , 2019, 10, 895-903.	1.0	20
11	<i>In vitro</i> study of the Polo-like kinase 1 inhibitor volasertib in non-small cell lung cancer reveals a role for the tumor suppressor p53. <i>Molecular Oncology</i> , 2019, 13, 1196-1213.	4.6	17
12	Authors' response letter: Quality of life in oropharyngeal cancer: a structured review of the literature. <i>Supportive Care in Cancer</i> , 2019, 27, 1583-1583.	2.2	0
13	Efficacy of nab-paclitaxel in treating metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 495-500.	1.8	7
14	Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients. <i>Head and Neck</i> , 2019, 41, 2197-2207.	2.0	14
15	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. <i>Cancers</i> , 2019, 11, 1893.	3.7	7
16	Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. <i>Quality of Life Research</i> , 2019, 28, 663-676.	3.1	23
17	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2019, 393, 156-167.	13.7	1,153
18	Nivolumab in squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 409-420.	2.4	9

#	ARTICLE	IF	CITATIONS
19	Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3144-3154.	3.6	156
20	Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 901-915.	2.4	40
21	Quality of life in oropharyngeal cancer: a structured review of the literature. <i>Supportive Care in Cancer</i> , 2018, 26, 2511-2518.	2.2	23
22	Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium. <i>Annals of Oncology</i> , 2018, 29, 1987-1994.	1.2	52
23	Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 3417-3423.	2.2	10
24	Pembrolizumab use for the treatment of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 765-780.	3.1	10
25	The prognostic value of the comprehensive geriatric assessment (CGA) in elderly cancer patients (ECP) treated with chemotherapy (CT): a systematic review. <i>European Journal of Cancer</i> , 2017, 72, S164-S165.	2.8	1
26	TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. <i>Annals of Oncology</i> , 2017, 28, 2219-2224.	1.2	18
27	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	4.1	32
28	Atypical Carcinoid Tumor of the Larynx: A Challenging Diagnostic Case. , 2016, 6, .		0
29	Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. <i>Medicinal Research Reviews</i> , 2016, 36, 749-786.	10.5	78
30	Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3803-3811.	4.1	34
31	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 811-826.	2.4	26
32	Nivolumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1247-1261.	2.4	20
33	A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators. <i>Journal of Nutrition, Health and Aging</i> , 2016, 20, 60-70.	3.3	26
34	Afatinib in squamous cell carcinoma of the head and neck. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1295-1301.	1.8	15
35	Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1629-1636.	1.6	6
36	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1146-1156.	1.2	197

#	ARTICLE	IF	CITATIONS
37	Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis. <i>Oncologist</i> , 2016, 21, 59-71.	3.7	16
38	Locoregionally advanced squamous cell carcinoma of the head and neck: chemoradiation or bioradiation. <i>Translational Cancer Research</i> , 2016, 5, 223-228.	1.0	4
39	Abstract 258: Is P53 the up-and-coming predictive biomarker for volasertib treatment in NSCLC. , 2016, , .		0
40	Long-term recurrence-free survival after hepatic resection for metachronous gastric cancer liver metastases. <i>Translational Cancer Research</i> , 2016, 5, 497-499.	1.0	0
41	CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation. <i>Annals of Translational Medicine</i> , 2016, 4, 432-432.	1.7	1
42	1560 Quality of life (QoL) evaluation in head and neck cancer (HNC) patients: Electronics beats paper. <i>European Journal of Cancer</i> , 2015, 51, S224.	2.8	0
43	2822 Gemcitabine-based chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: A literature review and meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, S565-S566.	2.8	0
44	Medical Cost Associated with Treatment and Follow-Up of Patients with Head and Neck Cancer. <i>Value in Health</i> , 2015, 18, A449.	0.3	2
45	Cost and Cost-Effectiveness Data on Pancreatic Cancer: a Comprehensive Review of the Literature. <i>Value in Health</i> , 2015, 18, A448-A449.	0.3	1
46	2817 12-year Follow-up (FU) Data and late local toxicity Of Two Cohorts of patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) treated with Concomitant Chemoradiation (CCRT) With Or Without Induction Chemotherapy (ICT). <i>European Journal of Cancer</i> , 2015, 51, S563.	2.8	1
47	Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?. <i>Trials</i> , 2015, 16, 395.	1.6	23
48	A phase I study of volasertib combined with afatinib, in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 843-851.	2.3	19
49	The Economics of the Treatment and Follow-Up of Patients with Glioblastoma. <i>Value in Health</i> , 2015, 18, A448.	0.3	5
50	Induction chemotherapy in squamous cell carcinoma of the head and neck: Saved by the bell?. <i>Oral Oncology</i> , 2015, 51, e5-e7.	1.5	2
51	Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. <i>Journal of Neurology</i> , 2015, 262, 742-751.	3.6	10
52	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 583-594.	10.7	358
53	A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 13-20.	2.3	30
54	Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 18.	3.0	11

#	ARTICLE	IF	CITATIONS
55	Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience. <i>Oncologist</i> , 2015, 20, 279-290.	3.7	3
56	Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck. <i>Current Clinical Pathology</i> , 2015, , 81-87.	0.0	0
57	Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. <i>American Journal of Cancer Research</i> , 2015, 5, 1921-38.	1.4	19
58	Phase 1B Study of Mehd7945A (Mehd) Plus Cisplatin/Fluorouracil (Cis/5Fu) or Carboplatin/Paclitaxel (Carbo/Pac) for 1St-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (Rmscchn). <i>Annals of Oncology</i> , 2014, 25, iv341.	1.2	3
59	Induction chemotherapy in head and neck cancer: are we too ambitious?. <i>Future Oncology</i> , 2014, 10, 337-340.	2.4	3
60	68 Can the P53 status predict the outcome of Polo-like kinase 1 inhibition in non-small cell lung cancer cell lines?. <i>European Journal of Cancer</i> , 2014, 50, 27.	2.8	0
61	Real World Management and Costs in Unresectable Metastatic Melanoma (UMM) Patients Treated at the Antwerp University Hospital (UZA). <i>Value in Health</i> , 2014, 17, A627.	0.3	0
62	Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. <i>BMC Research Notes</i> , 2014, 7, 337.	1.4	35
63	Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. <i>Cancer Letters</i> , 2014, 354, 365-377.	7.2	53
64	Real World Management and Costs in Unresectable Metastatic Melanoma (MM) Patients: Update of a Pilot Study Based on an Institutional Patient Registry. <i>Value in Health</i> , 2013, 16, A403.	0.3	0
65	Antineoplastic therapy-induced pulmonary toxicity. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 997-1006.	2.4	8
66	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. <i>Oncologist</i> , 2013, 18, 850-864.	3.7	82
67	Cetuximab: its unique place in head and neck cancer treatment. <i>Biologics: Targets and Therapy</i> , 2013, 7, 77.	3.2	62
68	Abstract 1030: The intriguing interplay between EGFR inhibitors and the hypoxic microenvironment: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.. , 2013, , .		0
69	Abstract 5628: Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP6.. , 2013, , .		0
70	Biologic Therapy in Head and Neck Cancer: A Road with Hurdles. <i>ISRN Oncology</i> , 2012, 2012, 1-15.	2.1	17
71	Bevacizumab in glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 9-18.	2.4	19
72	EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2012, 105, 238-240.	0.6	16

#	ARTICLE	IF	CITATIONS
73	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1511-1521.	2.4	6
74	PCN53 Real World Management and Costs in Metastatic Malignant Melanoma (MM) Patients: A Pilot Study Based on an Institutional Patient Registry. <i>Value in Health</i> , 2012, 15, A418.	0.3	0
75	Abstract 1898: Potential molecular mechanisms of intrinsic resistance to EGFR-targeting monoclonal antibodies in HNSCC. , 2012, , .		0
76	Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 472-477.	1.3	19
77	Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 185-191.	2.3	2
78	Expression Analysis on Archival Material. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 203-211.	2.1	16
79	Cetuximab in the treatment of squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 511-524.	2.4	40
80	Abstract 280: RNA isolation from formalin-fixed paraffin-embedded material: A comparison of five commercially available RNA isolation kits. , 2011, , .		0
81	Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study. <i>Anti-Cancer Drugs</i> , 2010, 21, 306-312.	1.4	1
82	A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy. <i>Oncologist</i> , 2010, 15, 699-731.	3.7	137
83	Optimal treatment for recurrent/metastatic head and neck cancer. <i>Annals of Oncology</i> , 2010, 21, vii252-vii261.	1.2	286
84	ACUTE HEMIPLEGIA CAUSED BY A RETROGRADE CEREBRAL VENOUS AIR EMBOLISM AFTER CENTRAL VENOUS CATHETER REMOVAL: AN ILLUSTRATIVE CASE.. <i>Acta Clinica Belgica</i> , 2010, 65, 51-53.	1.2	5
85	Advances in the systemic treatment of head and neck cancers. <i>Current Opinion in Oncology</i> , 2010, 22, 200-205.	2.4	22
86	Targeted Therapy in Combination with Chemotherapy in Recurrent and/or Metastatic Head and Neck Cancer. <i>European Oncology and Haematology</i> , 2010, 06, 43.	0.0	1
87	Current concepts for the management of head and neck cancer: Chemotherapy. <i>Oral Oncology</i> , 2009, 45, 409-415.	1.5	75
88	A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck. <i>BMC Cancer</i> , 2009, 9, 273.	2.6	7
89	Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 233-241.	2.3	18
90	O111. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology Supplement</i> , 2009, 3, 93.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck. <i>Anticancer Research</i> , 2009, 29, 5137-42.	1.1	5
92	Recurrent head and neck cancer: current treatment and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 375-391.	2.4	39
93	A non-randomized single-center comparison of induction chemotherapy (IC) followed by chemoradiation (CRT) versus CRT for locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). <i>Journal of Clinical Oncology</i> , 2008, 26, 17004-17004.	1.6	0
94	Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. <i>Annals of Oncology</i> , 2007, 18, 961-962.	1.2	26
95	Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemo-naïve patients with squamous cell carcinoma of the head and neck: long-term follow up data. <i>Annals of Oncology</i> , 2007, 18, 1856-1860.	1.2	16
96	The role of taxanes and targeted therapies in locally advanced head and neck cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 195-201.	2.4	17
97	Neoadjuvant chemotherapy in head and neck cancer: Should it be revisited?. <i>Cancer Letters</i> , 2007, 256, 166-177.	7.2	39
98	5536 POSTER A non-randomized single-centre comparison of induction chemotherapy followed by chemoradiation versus chemoradiation for locally-advanced squamous cell carcinoma of the head and neck. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 335.	2.2	0
99	Targeted therapies in head and neck cancer. <i>Targeted Oncology</i> , 2007, 2, 73-88.	3.6	15
100	JESSICA: an object-oriented hypermedia publishing processor. <i>Computer Networks</i> , 1998, 30, 281-290.	1.0	20
101	Sequential treatment with vindesine+ifosfamide+platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: A phase II trial. Data presented in part at the 61st Annual International Scientific Assembly of the American College of Chest Physicians, New York, NY, USA, 31 October 1995. <i>Lung Cancer</i> , 1998, 22, 45-53.	2.0	8
102	Treatment of intractable hiccup in a terminal cancer patient with nebulized saline. <i>Palliative Medicine</i> , 1996, 10, 166-167.	3.1	10
103	Minerva's comment was not evidence based. <i>BMJ: British Medical Journal</i> , 1996, 313, 113-113.	2.3	0
104	The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89. <i>Acta Urologica Belgica</i> , 1996, 64, 13-9.	0.1	2